Aurora, CO 80045, US
Biotechnology
www.sharklet.com
Sharklet Technologies, Inc. is a biotechnology company that develops and brings to market surface technologies that manage microorganisms to make the world a healthier, environmentally safer and better place.
The company’s patented, core technology, called Sharklet™, is the first no-kill, non-toxic and environmentally-friendly surface texture designed to inhibit bacterial growth including MRSA, E. coli, Staph a., Pseudomonas aeruginosa, VRE and a host of other bacteria. The Sharklet surface is comprised of millions of microscopic diamonds that are arranged into a distinct texture. It is this texture that bacteria find inhospitable for growth.
Inspired by the natural microbe-resistant properties of sharkskin, Sharklet is a simple solution for a complex problem. Sharklet is a platform technology with broad applications from germ-prone surfaces in healthcare and childcare facilities to consumer goods and medical devices. The company has already licensed its technology for a urinary catheter that is currently in clinical trials with the aim to reduce catheter-associated urinary tract infections.
-Medical Devices-Urinary Catheter, Airway Management (Endotracheal) Tube, Vascular Access , Ocular Implants (Intraocular Lens)
-Consumer Goods-Smart phone cases/screen protector
-Environmental Surfaces-Laminates, Surface Protection Films, Food/Pharmaceutical Packaging and Processing
Prior to joining Sharklet Technologies, Spiecker was the director of restructuring and investor relations for Adelphia Communications Corporation, the nation’s fifth largest U.S. cable operator at the time. He was instrumental in the sale of an Adelphia joint-venture cable system. Prior to that, Spiecker was responsible for client services and operations structure development at 360networks. He honed his leadership skills at home building products manufacturer Louisiana-Pacific Corporation as the head of human resources and process engineering. He also held roles in operations management with Tricon Global Restaurants.
Spiecker is an active community leader, serving as Vice-Chair of the Board of the Colorado BioScience Association and was appointed by the Governor of Colorado to serve as a Commissioner for the Early Childhood Leadership Commission as well as the Colorado Workforce Development Council. Spiecker earned a MBA and B.S.BA. in Marketing from Rockhurst University.
Dr. Reddy serves as VP of R&D and Principal Investigator for all the company’s product development work funded through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. She leads the R&D team in development of numerous medical and consumer products alongside industry partners under joint development efforts.
Dr. Reddy holds a PhD in chemical engineering from the University of Texas at Austin, where her research focused on microfluidics in the Step and Flash Imprint Lithography process. She earned a BSE degree in Chemical Engineering from Princeton University. She received a Humboldt Fellowship for Postdoctoral research at the Max Planck Institute in Stuttgart, Germany, researching the replication of biomimetic gecko setae for switchable adhesion on polymer surfaces. Her work has been published in numerous scientific journals including Clinical and Translational Research, American Journal of Infection Control, and Nanotechnology among others.
Dr. Anthony Brennan is the founder of STI and chairman of the company’s Scientific Advisory Board. Dr. Brennan discovered and developed Sharklet™. He is an endowed professor in the Department of Materials Science and Engineering and holds an appointment in the Biomedical Engineering department at the University of Florida. He is a world-renowned research engineer in surface sciences and acclaimed for his work in engineered microtopographies for microorganism control. Dr. Brennan serves as the associate director of the Center for Macromolecular Science and Engineering.
Within the business community, Dr. Brennan serves as a reviewer of numerous publications and a consultant to the medical device industry. He previously held an executive position at Coors Biomedical Company, which provided research and manufacturing in bio-ceramics for Johnson & Johnson.
Dr. Brennan received his Ph.D. in materials engineering science from Virginia Polytechnic Institute and State University.
Joe Bagan is chairman of the Sharklet Technologies’ board of directors. Bagan brings more than 20 years of strategic leadership and executive management experience to the company. In addition to being a founder and former CEO of Sharklet Technologies, Bagan is co-founder of RevGen Partners, a consultancy focused on revenue audit/assurance and business intelligence and optimization for companies of all sizes.
Before his work in life-sciences, Bagan held a number of executive positions in the telecommunications, cable TV and media industries. These includeL COO of Clear Channel Outdoor, senior vice president of Adelphia Communications’ southeast region, CAO at Adelphia, CFO at Ricochet Wireless Networks. Bagan also has expertise in leading large organizations as he served in various executive capacities at AT&T Broadband from 2000 to 2002. Prior to AT&T Bagan was recruited from Arthur Andersen where he was the partner in charge of the Southwestern United States’ consulting practice.
Jason Morton is a seasoned management executive with more than 20 years of experience designing, developing, and commercializing medical devices across broad medical market segments including ear/nose/throat, orthopedic, pain management, hospital bedside and pharmacy devices. Morton brings extensive experience establishing and optimizing functional teams in product development, operations, quality assurance, and clinical affairs for start-ups to large enterprises, VC-backed to Fortune 500 companies.
Morton has a track record of developing cutting-edge technologies to match customer needs with emerging business strategies. Morton worked for a number of start-ups establishing US and EU regulatory compliant operations and quality systems to support product development initiatives for FDA clearance and CE marking. Morton received his BS in Mechanical Engineering from Colorado State University and his MBA from the University of Denver.
Dr. Dannemiller serves as Chief Medical Officer for Sharklet Technologies and advises the company on the application of Sharklet in healthcare environments. In addition to her advisory role, she is an emergency medicine physician and associate medical director of the Emergency Department at Northern Colorado Medical Center, a level-2 trauma center with 55,000 annual visits. Prior to practicing emergency medicine, Dr. Dannemiller worked as a consultant at McKinsey and Company and spent time at Genentech in drug development. Additionally, she served on the board of the Denver Business Series. Dr. Dannemiller graduated from the University of Virginia with a B.S. in Commerce. She completed medical school at Georgetown University and business school at Harvard University. She is board certified in Emergency Medicine and is a member of the American College of Emergency Physicians and completed her residency in Emergency Medicine at Denver Health.